STAT's Adam Feuerstein and Damian Garde are tracking an FDA advisory panel's hearing on the Alzheimer's treatment Leqembi.June 9, 2023Check out STAT+Sponsored By ADOBE, Alex Hogan/STAT STAT+ | How a now-retracted study got published in the first place, leading to a $3.8 million NIH grant The journal's chief editor initially rejected the paper on the reviewers' advice — but then accepted it with some changes to its text. By Ellie Kincaid — Retraction Watch STAT+ | Tracking the FDA advisory panel on Eisai and Biogen's treatment for Alzheimer's disease STAT's Adam Feuerstein and Damian Garde are tracking the meeting about Leqembi, an Alzheimer's treatment developed by Eisai and Biogen. By Adam Feuerstein and Damian Garde FDA's letter to medical device maker iRhythm is a warning for the industry The FDA issued a warning to medical device maker iRhythm for marketing its product for "high risk" patients. By Lizzy Lawrence Adobe Opinion: Why we created a chatbot to help people at risk for eating disorders Tessa was never intended to replace the NEDA Helpline or to help people who currently are in the throes of an eating disorder. By Ellen Fitzsimmons-Craft and C. Barr Taylor STAT+ | Updated data show long-term benefits of CRISPR treatment for sickle cell, beta thalassemia New results showed the one-time therapy helped people live free of pain and transfusions for over a year. By Andrew Joseph STAT+ | 'Stung' by Pear's bankruptcy, a state Medicaid program pauses on digital therapeutics After getting burned by Pear's bankruptcy, Oklahoma Medicaid officials are hesitant on digital therapeutics for health care. By Mario Aguilar Ruby Wallau for STAT STAT+ | Trailing other sickle cell drug makers, Editas still sees opportunity for its CRISPR therapy Even as other genetic therapies for sickle cell move closer to approval, CRISPR company Editas sees a commercial opportunity for its product. By Andrew Joseph Opinion: Your health insurance may not be as good your state requires — and it's perfectly legal I'm a health researcher, and yet even I was stunned to find out I wasn't eligible for protections I knew had passed in my state. By Shira Fischer More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments